Possibility of treatment modification in patients with ankylosing spondylitis achieved of partial remission on treatment with adalimumab: Real practice data
Objective. To assess the duration of remission or inactive disease status in patients with achieved partial remission due to treatment with adalimumab (ADA) after it discontinuation.Materials and methods. A dynamic observation was conducted of 26 patients with ankylosing spondylitis with partial rem...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2021-01-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2969 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849400818858459136 |
|---|---|
| author | A. V. Petrov Ya. O. Shevnina A. S. Gaffarova N. V. Matveeva |
| author_facet | A. V. Petrov Ya. O. Shevnina A. S. Gaffarova N. V. Matveeva |
| author_sort | A. V. Petrov |
| collection | DOAJ |
| description | Objective. To assess the duration of remission or inactive disease status in patients with achieved partial remission due to treatment with adalimumab (ADA) after it discontinuation.Materials and methods. A dynamic observation was conducted of 26 patients with ankylosing spondylitis with partial remission achieved due to prolonged use (for 24 months or more) of subcutaneous injections of 40 mg ADA once every two weeks. The discontinuation of ADA was carried out after a 3-4 month period of its use in de-escalation mode in the form of 1 injection (40 mg) once every 4 weeks. After discontinuation of ADA, patients continued to take non-steroidal anti-inflammatory drugs, sulfasalazine at a dose of 1.5-2 g per day (11 patients) and methotrexate 10 mg per week (3 patients). Assessment of the clinical, laboratory and ultrasonographic parameters of ankylosing spondylitis was carried out in 3, 6 and 12 months after the abolition of the ADA.Results and discussion. Among the observed patients, partial clinical remission of ankylosing spondylitis maintained after 6 months in 12 (46.2%) patients, and after 12 months - in 10 (38.5%). A low degree of ankylosing spondylitis activity (BASDAI <4) was maintained for 6 months after the abolition of ADA in 14 (53.8%) patients, and after 12 months - in 12 (46.2%).Conclusion. Within 12 months after cancellation of ADA, ankylosing spondylitis exacerbation was observed in 53.8% of patients with initially achieved partial clinical remission. |
| format | Article |
| id | doaj-art-2c71e0d38a534ede8b8d42fa0bb9dc10 |
| institution | Kabale University |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2021-01-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-2c71e0d38a534ede8b8d42fa0bb9dc102025-08-20T03:37:54ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922021-01-0158669169410.47360/1995-4484-2020-691-6942666Possibility of treatment modification in patients with ankylosing spondylitis achieved of partial remission on treatment with adalimumab: Real practice dataA. V. Petrov0Ya. O. Shevnina1A. S. Gaffarova2N. V. Matveeva3Medical Academy named after S.I. Georgievsky of Vernadsky CFUCrimean Republican Clinical Hospital named after N.A. SemashkoMedical Academy named after S.I. Georgievsky of Vernadsky CFUMedical Academy named after S.I. Georgievsky of Vernadsky CFUObjective. To assess the duration of remission or inactive disease status in patients with achieved partial remission due to treatment with adalimumab (ADA) after it discontinuation.Materials and methods. A dynamic observation was conducted of 26 patients with ankylosing spondylitis with partial remission achieved due to prolonged use (for 24 months or more) of subcutaneous injections of 40 mg ADA once every two weeks. The discontinuation of ADA was carried out after a 3-4 month period of its use in de-escalation mode in the form of 1 injection (40 mg) once every 4 weeks. After discontinuation of ADA, patients continued to take non-steroidal anti-inflammatory drugs, sulfasalazine at a dose of 1.5-2 g per day (11 patients) and methotrexate 10 mg per week (3 patients). Assessment of the clinical, laboratory and ultrasonographic parameters of ankylosing spondylitis was carried out in 3, 6 and 12 months after the abolition of the ADA.Results and discussion. Among the observed patients, partial clinical remission of ankylosing spondylitis maintained after 6 months in 12 (46.2%) patients, and after 12 months - in 10 (38.5%). A low degree of ankylosing spondylitis activity (BASDAI <4) was maintained for 6 months after the abolition of ADA in 14 (53.8%) patients, and after 12 months - in 12 (46.2%).Conclusion. Within 12 months after cancellation of ADA, ankylosing spondylitis exacerbation was observed in 53.8% of patients with initially achieved partial clinical remission.https://rsp.mediar-press.net/rsp/article/view/2969ankylosing spondylitispartial clinical remissionadalimumabasdas-crpindexbasdai index |
| spellingShingle | A. V. Petrov Ya. O. Shevnina A. S. Gaffarova N. V. Matveeva Possibility of treatment modification in patients with ankylosing spondylitis achieved of partial remission on treatment with adalimumab: Real practice data Научно-практическая ревматология ankylosing spondylitis partial clinical remission adalimumab asdas-crpindex basdai index |
| title | Possibility of treatment modification in patients with ankylosing spondylitis achieved of partial remission on treatment with adalimumab: Real practice data |
| title_full | Possibility of treatment modification in patients with ankylosing spondylitis achieved of partial remission on treatment with adalimumab: Real practice data |
| title_fullStr | Possibility of treatment modification in patients with ankylosing spondylitis achieved of partial remission on treatment with adalimumab: Real practice data |
| title_full_unstemmed | Possibility of treatment modification in patients with ankylosing spondylitis achieved of partial remission on treatment with adalimumab: Real practice data |
| title_short | Possibility of treatment modification in patients with ankylosing spondylitis achieved of partial remission on treatment with adalimumab: Real practice data |
| title_sort | possibility of treatment modification in patients with ankylosing spondylitis achieved of partial remission on treatment with adalimumab real practice data |
| topic | ankylosing spondylitis partial clinical remission adalimumab asdas-crpindex basdai index |
| url | https://rsp.mediar-press.net/rsp/article/view/2969 |
| work_keys_str_mv | AT avpetrov possibilityoftreatmentmodificationinpatientswithankylosingspondylitisachievedofpartialremissionontreatmentwithadalimumabrealpracticedata AT yaoshevnina possibilityoftreatmentmodificationinpatientswithankylosingspondylitisachievedofpartialremissionontreatmentwithadalimumabrealpracticedata AT asgaffarova possibilityoftreatmentmodificationinpatientswithankylosingspondylitisachievedofpartialremissionontreatmentwithadalimumabrealpracticedata AT nvmatveeva possibilityoftreatmentmodificationinpatientswithankylosingspondylitisachievedofpartialremissionontreatmentwithadalimumabrealpracticedata |